RALA and cancer: The Ral (Ras‐like) proteins, a subset of the Ras subfamily, have emerged as critical targets in cancer therapy.36 500 000 compounds were screened in silico in a pocket identified in RalA‐GDP that is not present in the RalA or B GNP structure.37 It was anticipated that compounds binding in this pocket would prevent the activation of the Ral GTPases by their GEFs.